3-nitrophenyldisulphide | 941585-08-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-nitrophenyldisulphide
• 英文别名: 3-nitrophenyldisulfide；1-(Disulfanyl)-3-nitrobenzene
• CAS: 941585-08-6
• 化学式: C₆H₅NO₂S₂
• 分子量: 187.243
• InChiKey: LVWOTSKDJBTAGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-N-[2-chloro-4-iodophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide 、 3-nitrophenyldisulphide 以 二苯醚 为溶剂， 生成 (R)-N-[2-Chloro-4-(3-nitrophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide
  参考文献：
  名称：

  Use of compounds for the elevation of pyruvate dehydrogenase activity

  摘要：

  该公式（I）的化合物及其盐的使用；以及该公式（I）的药学上可接受的体内可降解前药；以及该化合物的药学上可接受的盐或前药：其中：环C是苯或与之相连的碳链杂环，其被定义为取代；R1是被定义为邻位取代基；n为1或2；A—B是被定义为连接基；R2和R3如所定义；R4是羟基、氢、卤素、氨基或甲基；用于制造用于提高温血动物（如人类）PDH活性的药物的描述。还描述了该公式（I）化合物的制备的药物组合物、方法和过程。

  公开号：

  US06498275B1

文献信息

• PYRAZINECARBOXAMIDE COMPOUND
  申请人：ASTELLAS PHARMA INC.

  公开号：US20140323463A1

  公开（公告）日：2014-10-30

  [Problem] A compound which is useful as an inhibitor on EGFR T790M mutation kinase activity is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory action on an EGFR T790M mutation kinase, and have found that a pyrazinecarboxamide compound has an inhibitory action on an EGFR T790M mutation kinase, thereby completing the present invention. The pyrazinecarboxamide compound of the present invention has an inhibitory action on an EGFR T790M mutation kinase, and can be used as an agent for preventing and/or treating EGFR T790M mutation positive cancer, in another embodiment, EGFR T790M mutation positive lung cancer, in a still other embodiment, EGFR T790M mutation positive non-small cell lung cancer, in further still another embodiment, EGFR T790M mutation protein positive cancer, in further still another embodiment, EGFR T790M mutation protein positive lung cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant lung cancer, and in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer, or the like.

  提供一种作为EGFR T790M突变激酶活性抑制剂的化合物。 解决方案的手段 本发明人调查了一种对EGFR T790M突变激酶具有抑制作用的化合物，并发现吡嗪羧酰胺化合物对EGFR T790M突变激酶具有抑制作用，从而完成了本发明。本发明的吡嗪羧酰胺化合物对EGFR T790M突变激酶具有抑制作用，并可用作预防和/或治疗EGFR T790M突变阳性癌症的药剂，在另一实施例中，EGFR T790M突变阳性肺癌，在另一实施例中，EGFR T790M突变阳性非小细胞肺癌，在进一步的另一实施例中，EGFR T790M突变蛋白阳性癌症，在进一步的另一实施例中，EGFR T790M突变蛋白阳性肺癌，在进一步的另一实施例中，EGFR酪氨酸激酶抑制剂耐药癌症，在进一步的另一实施例中，EGFR酪氨酸激酶抑制剂耐药肺癌，在进一步的另一实施例中，EGFR酪氨酸激酶抑制剂耐药非小细胞肺癌等。
• N-alkylthio beta-lactams, alkyl-coenzyme a asymmetric disulfides, and aryl-alkyl disulfides as anti-bacterial agents
  申请人：Turos Edward

  公开号：US20080182815A1

  公开（公告）日：2008-07-31

  The present invention provides N-alkylthio β-lactams and disulfide compounds (e.g., alkyl-coenzyme A asymmetric disulfides or aryl-alkyl disulfides), compositions containing such compounds, and method of their use as anti-bacterial agents.

  本发明提供了N-烷基硫代β-内酰胺和二硫化合物（例如，烷基辅酶A不对称二硫化合物或芳基-烷基二硫化合物），含有这些化合物的组合物，以及将它们用作抗菌剂的方法。
• [EN] SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS<br/>[FR] FORMES SOLIDES DE SULFONAMIDES ET D'ACIDES AMINÉS
  申请人：PLEXXIKON INC

  公开号：WO2010129570A1

  公开（公告）日：2010-11-11

  Solid forms of phenyl sulfonamide compounds of formula (I) active on protein kinases, including Raf protein kinases, are described, as well as methods of using such solid forms to treat diseases and conditions associated with activity of protein kinases, e.g. Raf protein kinases, including pain, polycystic kidney disease, melanoma and colorectal cancer.

  本文描述了公式（I）的苯基磺酰胺化合物的固体形式，其在蛋白激酶中具有活性，包括Raf蛋白激酶，以及使用这些固体形式治疗与蛋白激酶活性相关的疾病和病况的方法，例如疼痛、多囊肾病、黑色素瘤和结直肠癌。
• Indole derivatives useful as progesterone receptor modulators
  申请人：Jiang Weiqin

  公开号：US20060111427A1

  公开（公告）日：2006-05-25

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical uses of these compounds are related to contraception, the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minication of side effects of cyclid menstrual bleeding. Additional uses of the invention include stimulation of food intake.

  本发明涉及新型吲哚衍生物、含有它们的制药组合物及其在治疗或预防由孕激素受体激动剂和拮抗剂介导的疾病和疾病中的应用。这些化合物的临床用途与避孕、治疗和/或预防继发性闭经、功能性出血、子宫肌瘤、子宫内膜异位症、多囊卵巢综合征、子宫内膜癌和腺癌、卵巢、乳房、结肠、前列腺癌或减少周期性月经出血的副作用有关。本发明的其他用途包括促进食物摄入。
• INDOLE DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS
  申请人：Jiang Weiqin

  公开号：US20070135511A1

  公开（公告）日：2007-06-14

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical uses of these compounds are related to contraception, the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minication of side effects of cyclid menstrual bleeding. Additional uses of the invention include stimulation of food intake.

  本发明涉及新型吲哚衍生物、含有它们的制药组合物以及它们在治疗或预防由孕激素受体激动剂和拮抗剂介导的疾病和疾病中的应用。这些化合物的临床用途涉及避孕、治疗和/或预防继发性闭经、功能性出血、子宫平滑肌瘤、子宫内膜异位症、多囊卵巢综合症、子宫内膜癌和腺癌、卵巢、乳房、结肠、前列腺癌或减少月经出血的副作用。本发明的其他用途包括促进食物摄入。